image header

Investor Overview

Investor Overview

ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Our lead candidate, evorpacept (ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated proprietary Fc domain. We have developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities.

ALX Oncology

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

Sep 16, 2021

ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma Read more

Sep 7, 2021

ALX Oncology Announces Upcoming Virtual Investor Conference Participation Read more

Aug 12, 2021

ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights Read more

Upcoming Events

Sep 28, 2021 at 11:50 AM EDT

Cantor Virtual Global Healthcare Conference